S14 Ep57: Cevostamab-Based Regimens Usher In the Next Wave of Bispecific Antibody Strategies in R/R Myeloma: With Joshua Richter, MD

OncLive® On Air - A podcast by OncLive® On Air

Podcast artwork

Dr Richter discusses the rationale for targeting FcRH5 in myeloma and the evaluation of cevostamab-based combination strategies in this disease.

Visit the podcast's native language site